Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer

Study acronym: PALANGI
StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 16 words
  2. Primary and study completion dates pushed to Jan 19, 2011
    • Start date: Sep 2006 to Sep 25, 2009
    v4
  3. Trial status: Active, Not Recruiting to Completed
    • Study description shortened, about 8 words
    v3
  4. Trial status: Recruiting to Active, Not Recruitingv2 Show 6 more changesShow less
    • Primary completion date: Jan 2009
    • Study completion date: Sep 2008 to Jul 2009
    • Interventions: Cyclophosphamide (Drug), Megestrol (Drug) to CYCLOPHOSPHAMIDE (Drug), MEGESTROL (Drug)
    • Secondary endpoints revised (5)
    • Site details revised at 4 of 4 sites
    • Study arms: 0 to 2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The scope of the trial is to assess the free progression rate at 2 months for each group of patients.
Trial Details
NCT Number NCT00420563
Lead Sponsor Centre Oscar Lambret
Conditions
(from sponsor)		 Cancer
Related terms Neoplasms
Enrollment 88 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov